Real-World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real-World Analysis - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Assessment of Talquetamab in Treating Relapsed/Refractory Multiple Myeloma: Insights from an International Immunotherapy Registry Analysis

  • By

  • Murali Janakiram

  • Carlyn R. Tan

  • Hira Mian

  • Chiung-Yu Huang

  • Rakesh Popat

  • Joaquín Martínez-Lopez

  • Efsthathios Kastritis

  • Wee-Joo Chng

  • Prashant Kapoor

  • Mrugakshi Dave

  • Susan Bal

  • Laurent Garderet

  • Andre De Menezes Silva Corraes

  • Christine Riedhammer

  • Torsten Steinbrunn

  • Magdalene Corona

  • Chandramouli Nagarajan

  • Hermann Einsele

  • Tom Martin

  • Amrita Krishnan

  • Yi Lin

  • May 19, 2026

Share

  • 1

    Talquetamab is a bispecific antibody approved for relapsed refractory multiple myeloma after four prior lines of therapy.

  • 2

    In the MonumenTAL-1 study, talquetamab achieved an overall response rate of 74% with 0.4 mg/kg weekly dosing.

  • 3

    Adverse events associated with talquetamab include cytokine release syndrome, neurotoxicity, and skin-related toxicities.

  • 4

    A total of 151 patients were included in the real-world analysis, with a median age of 64 years and a median of 6 prior therapy lines.

  • 5

    Skin toxicities occurred in 40% of patients, with most being mild to moderate and requiring minimal specific treatment.

Original Source(s)

Real-World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real-World Analysis

  • by Murali Janakiram, Carlyn R. Tan, Hira Mian, Chiung-Yu Huang, Rakesh Popat, Joaquín Martínez-Lopez, Efsthathios Kastritis, Wee-Joo Chng, Prashant Kapoor, Mrugakshi Dave, Susan Bal, Laurent Garderet, Andre De Menezes Silva Corraes, Christine Riedhammer, Torsten Steinbrunn, Magdalene Corona, Chandramouli Nagarajan, Hermann Einsele, Tom Martin, Amrita Krishnan, Yi Lin

  • May 19, 2026

Related Content

Large-cohort screening projects in seven regions of China demonstrate the efficacy of extended HPV genotyping in triaging HPV-positive women

Musings from The Power List: Dajun Yang

The Ascentage Pharma CEO on why next-generation small molecules are expanding into territory once reserved for biologics

  • September 15, 2026

  • 5 min
Dana-Farber/Boston Children's Named the Top Pediatric Cancer Program in the Nation for 2026-2027

U.S. News & World Report has recognized Dana-Farber/Boston Children’s Cancer and Blood Disorders Center as the #1 pediatric cancer program in the nation in its 2026-2027 Best Children’s Hospitals report.

  • by

  • September 15, 2026

  • 3 min